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Introduction
The episodic release of growth hormone (GH) from
pituitary somatotrophs results from a complex inter-
play primarily between two hypothalamic peptides,
the stimulatory GH-releasing hormone (GHRH) and
the inhibitory somatostatin (SST) (1). Activation of
the GH secretagogue receptor (GHS-R) in hypothal-
amus and pituitary further modulates the actions of
the two classically defined regulators of GH secretion
(2). Direct measurement of GHRH and SST in
hypophyseal-portal blood of male rats indicates a
rhythmic pattern of release of these two neuropep-
tides at regular 3- to 4-hour intervals about 180° out
of phase (3). In contrast, female rats appear to have a
different release pattern of the two peptides charac-
terized by continuous secretion of SST and episodic,
rather than rhythmic bursts of GHRH. As a result,
GH secretory profiles in females are distinct from
males and may account for the striking sex difference
in somatic growth (4). Male rats exhibit narrow GH
pulses with a frequency of about one pulse every 3–4
hours and prolonged nadir values below 1–2 ng/ml.
Female rats exhibit relatively broader pulses with an
irregular frequency and nadir values of 5–20 ng/ml
(4). In humans, a similar sexual diergism (functional
dimorphism) of GH secretion exists between men
and women, indicating phylogenetic conservation of
neuroendocrine hormone rhythms (5).
The underlying mechanisms for such a sharp sex-spe-
cific difference in GH secretion remain unclear. Periven-
tricular hypothalamic SST peptide and mRNA levels
are higher in male compared with female rats and mice
(6, 7), leading to the suggestion that sex differences in
hypothalamic SST signaling to pituitary somatotrophs
play a key role in the sexually diergic GH responses (1).
Ontogenic studies have demonstrated that these dif-
ferences are first evident at postnatal day 5 and contin-
ue to develop in an orderly cascade through puberty
into adulthood (8, 9). There are five known SST recep-
tors (SSTRs) with distinct cellular distributions and
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Pulsatile growth hormone (GH) secretion differs between males and females and regulates the sex-
specific expression of cytochrome P450s in liver. Sex steroids influence the secretory dynamics of GH,
but the neuroendocrine mechanisms have not been conclusively established. Because periventricu-
lar hypothalamic somatostatin (SST) expression is greater in males than in females, we generated
knockout (Smst–/–) mice to investigate whether SST peptides are necessary for sexually differentiated
GH secretion and action. Despite marked increases in nadir and median plasma GH levels in both
sexes of Smst–/– compared with Smst+/+ mice, the mutant mice had growth curves identical to their sib-
ling controls and retained a normal sexual dimorphism in weight and length. In contrast, the liver
of male Smst–/– mice was feminized, resulting in an identical profile of GH-regulated hepatic mRNAs
between male and female mutants. Male Smst-/- mice show higher expression of two SST receptors in
the hypothalamus and pituitary than do females. These data indicate that SST is required to mas-
culinize the ultradian GH rhythm by suppressing interpulse GH levels. In the absence of SST, male
and female mice exhibit similarly altered plasma GH profiles that eliminate sexually dimorphic liver
function but do not affect dimorphic growth.
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subtle differences in intracellular signaling that medi-
ate the actions of SST peptides (10). Furthermore, sex-
ual diergism has been noted for expression of SSTR1, 2,
3, and 5 in the anterior pituitary and for SSTR1 but not
SSTR2 in the rat hypothalamus (11–13). Although
estrogen and testosterone both influence hypothalam-
ic Smst gene expression and play a major developmental
role in organizing the sexual diergism of GH secretion,
the effect of gonadal steroids is not limited to the criti-
cal perinatal period of imprinting. Treatment of adults
with either 17-β-estradiol or testosterone feminizes or
masculinizes the GH secretory profile of male and
female rats, respectively (14, 15).
Sex differences in GH pulsatility are ultimately respon-
sible for sexual differentiation of the liver, a major target
organ of GH (4). In particular, many members of the
cytochrome P450 (CYP) and the major urinary protein
(MUP) gene families are differentially regulated by the
sex-specific pattern of GH secretion (16, 17). A key deter-
minant of hepatic gene regulation in males is the long
interpulse nadir of GH levels, which permits the resensi-
tization of GH receptor signaling by Janus kinase/signal
transducer and activation of transcription (JAK-STAT)
cascades (18) specifically involving STAT 5a and 5b pro-
teins (19–23). The hepatic microsomal enzymes regulat-
ed by GH have important physiological roles in the
hydroxylation and metabolism of both endogenous
steroid hormones and xenotoxins, thereby providing a
possible link between sexual differentiation of the brain
and sex differences in susceptibility to chemical toxicity
and carcinogenicity (24).
The goal of our present studies was to test directly
the hypothesis that SST is a physiological determi-
nant of masculinized GH secretory dynamics and sex-
ually dimorphic patterns of somatic growth.
Immunological, antisense, and pharmacological
approaches to the abrogation of SST function all have
important limitations in their selectivity, specificity,
and extent of action. Although both the SSTR2 and
SSTR1 genes have been knocked out in mice (25, 26),
there have been no reports on the consequences of
these mutations for sexually dimorphic GH release in
vivo. Therefore, we chose to address this problem by
the generation of gene-knockout mice lacking all
forms of proSST-derived peptide ligands. We then
analyzed growth, expression of SSTR1-5 in hypothal-
amus and pituitary gland, and GH secretion by a
combination of direct and indirect assays in both
sexes of somatostatin-deficient mice.
Methods
Gene targeting. Mouse genomic DNA fragments used for
construction of the Smst targeting vector were isolated
from a 129S6 cosmid library, generated by standard tech-
niques in our laboratory, by hybridization to a rat SST
cDNA probe (27). E14TG2A embryonic stem (ES) cells
derived from 129P2/OlaHsd mice were electroporated
and selected in G418 as described previously (28). Homol-
ogous recombination of both long and short arms was
confirmed by Southern blot analysis of genomic DNA,
and correctly targeted ES cells were microinjected into
C57BL/6J (The Jackson Laboratory, Bar Harbor, Maine,
USA) blastocysts to generate the founder chimeric mice.
Chimeric males were mated with C57BL/6J females, and
the resulting F1 offspring were crossed to produce F2
hybrid mice (129P2/OlaHsd, C57BL/6J). F1 heterozy-
gotes (Smst+/–) were also backcrossed for five successive
generations to produce N5 incipient congenic C57BL/6J
mice. Genotyping was performed by touchdown PCR
using three primers: R460 (SST sense) 5′-AGTTTCTGCA-
GAAGTCTCTGGC-3′; S229 (PGK-neo sense) 5′-CTAAAGCG-
CATGCTCCAGAC-3′; and R465 (SST antisense) 5′-
CAGGATGTGAATGTCTTCCAG-3′.
DNA fragments of 950 and 450 bp were amplified
from the wild-type (+) and mutant (–) alleles, respec-
tively. Phenotypic analyses were first performed using
sibling offspring from Smst+/– F1 mating pairs and were
then confirmed and extended using sibling offspring
from Smst+/– N5 mating pairs. All procedures involving
mice were approved by the Institutional Animal Care
and Use Committee and followed the Public Health
Service’s guidelines.
Histology and immunocytochemistry. Histological analy-
ses were performed on tissue fixed in 4% paraformalde-
hyde, and 50-µm sections of brain were collected with
a vibratome. Sections were incubated with 5% normal
goat serum followed by incubation with one of the fol-
lowing primary antisera at the indicated dilutions:
anti–SST-14 (1:2,000) (29); anti-SST prohormone cryp-
tic peptide (1:1,000) (29); anti-mouse GHRH (1:5,000)
(30); or one of a panel of anti-peptide SSTR1-5 antisera
1:400 (31) at 4°C overnight. With intervening washes
in Tris-buffered saline, the sections were incubated
with biotinylated goat anti-rabbit secondary antibody
at room temperature for 30 minutes, followed by expo-
sure to avidin-biotin horseradish peroxidase complex
(Vectastain Elite ABC Kit; Vector Laboratories,
Burlingame, California, USA) in PBS at room temper-
ature for 30 minutes. The reaction was revealed by
chromagen diaminobenzidine containing 0.1% hydro-
gen peroxide and yielded a brown reaction product.
Controls used to validate the specificity of the SSTR
immunoreactivity included preimmune serum in place
of primary antibody and primary antibody adsorbed
with excess antigen.
Hormone assays. Hormone levels were measured in
tissue extracts or plasma (27) using an SST RIA
(Peninsula Laboratories Inc., San Carlos, California,
USA) and rat IGF-1 RIA (Diagnostic Systems Labora-
tories Inc., Webster, Texas, USA) according to the
manufacturers’ instructions. For mouse GH RIA, a
double-antibody method was employed, using highly
purified mouse GH (AFP10873B) as the iodinated lig-
and, anti-rat GH (NIDDK–anti-rat GH-S5) as the pri-
mary antibody, and mouse GH (AFP10873B) as the
“cold standard,” or reference preparation. These
immunoreagents were developed by A.F. Parlow
(National Hormone and Peptide Program). The assay
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has a minimum sensitivity of 0.5 ng/ml using 10 µl
plasma. Inter- and intra-assay variations were 9% and
5%, respectively. Estradiol, testosterone, and thyrox-
ine were quantified by core RIA laboratories using
standard methodologies.
Semiquantitative RT-PCR analysis. mRNAs for 
SSTR1-5, SST, and cortistatin (CST) were analyzed by
semiquantitative RT-PCR using modifications of meth-
ods described elsewhere (32). Total RNA was isolated
from pools of hypothalamic blocks or whole pituitary
glands obtained from 16 each of male and female
Smst+/+ and Smst–/– mice using the guanidine-isothio-
cyanate phenolchloroform extraction method. The
RNA was reverse transcribed, and the resulting cDNA
samples were amplified by PCR using rat SSTR1-5 and
mouse SST and CST primers. The sequences for SSTR1-
5 primers have been published previously (32). The
primers used for SSTR2 only amplify the mouse
SSTR2A isoform. The following primers were used for
PCR amplification of SST and CST: SST (sense) 5′-
GCTCCCTCGGACCCCAGACTG-3′ (nucleotides [nt]
73–93); SST (antisense) 5′-ACAGGATGTGAAT-
GTCTTCCAG-3′ (nt 992–1013); CST (sense) 5′-TGGCC-
GAGGCACAGGAGGCAAG-3′ (nt 9–30); and CST (anti-
sense) 5′-TCAGGTCTCGTTGGCATCTCACA-3′ (nt
1413–1435). The SSTRs and SST and CST cDNAs were
coamplified with β-actin. PCR products were separated
by electrophoresis, and Southern blots were probed
with [32P]-labeled cDNA probes followed by autoradi-
ography and densitometric quantitation. Values of
SSTR1-5 mRNA expression were normalized to those of
β-actin mRNA on the same gels. All experiments were
performed four times, and each mRNA quantification
represents the average of at least three measurements.
Northern blots of liver mRNA. Total RNA was prepared
from 100 mg of liver homogenized in 3 ml of 4 M
guanidinium and electrophoresed on 1.5% agarose
formaldehyde gels. After RNA transfer, the Duralon
nylon membranes (Stratagene, La Jolla, California,
USA) were sequentially hybridized with [32P]-radiola-
beled probes, imaged on a Molecular Dynamics phos-
phorimager (Molecular Dynamics, Sunnyvale, Califor-
nia, USA), stripped, and rehybridized. Antisense
oligodeoxynucleotide sequences used for end labeling
with T4 DNA kinase were (MUPs I/II) 5′-GAG-
CACTCTTCATCTCTTACAGT-3′; (MUPs III) 5′-TCGCAGT-
CATTTCGGTGC-3′; (albumin) 5′-TCTACAGCAGGGCT-
GCCTCG-3′ (18S RNA) 5′-ACGGTATCTGATCGTCTT-
CGAACC-3′. Mouse cDNA sequences used for random-
primer labeling were a 500-bp NcoI-BamHI prolactin
receptor (33) and a 550-bp BamHI-EcoRI Cyp450-
15α2A4 (34) cloned fragments.
Statistics. Data were analyzed by multifactor ANOVA
using StatView Power PC version for Macintosh (ver-
sion 5.1; SAS Institute Inc., Cary, North Carolina,
USA) except where otherwise stated. Post hoc com-
parisons between groups were performed by Fisher’s
protected least significant difference (PSLD), and P
values < 0.05 were considered significant. GH data
sets with different means were compared by χ2 analy-
ses after calculating Z scores [Z = (x – µ)/σ] for each
data point. The Z transformation permits an approx-
imation of the probabilities for each x using the
probabilities derived from a standard normal distri-
bution (µ = 0; σ = 1).
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Figure 1
Generation of SST-deficient mice by homologous recombination. (a)
Restriction maps of the mouse Smst gene locus (top), targeting vec-
tor (middle), and predicted Smst null allele after homologous recom-
bination (bottom) indicate the replacement of exon 1 (E1) and the
Smst promoter by a PGK-neomycin selection cassette (neo). B, BamHI;
S, SalI; H, HindIII; C, ClaI; Ss, SspI. (b) A Southern blot of genomic
DNA digested with SalI and SspI was hybridized with the 3′ probe indi-
cated in a. The 6.0-kb band represents the wild-type allele and the
7.4-kb band represents the Smst null allele in the offspring of an
Smst+/– mating pair. (c) RIA of SST in extracts of stomach and total
brain (n = 3) demonstrates a 50% reduction in Smst+/– mice and lev-
els below the assay sensitivity in Smst–/– mice. (d) Hemicoronal hypo-
thalamic sections at the level of the periventricular nucleus (PeVN)
and anterior paraventricular nucleus (PVN) of an Smst+/+ and an
Smst–/– male mouse were immunostained for SST. There is a dense
network of immunopositive perikarya and fibers adjacent to the third
ventricle (III) only in the Smst+/+ mouse. These signals were also absent
after preadsorption of the antiserum with synthetic SST (data not
shown). Bars = 100 µm. (e) The median eminence (me) of an Smst+/+
and an Smst –/– mouse were immunostained for SST prohormone.
There is no detectable immunoreactivity in the external zone of the
me in the Smst–/– mouse. (f) The arcuate nucleus (Arc) of an Smst+/+
and an Smst–/– male mouse immunostained for GHRH. Immunore-
active neuronal perikarya are indicated by the arrows. No difference
is apparent between genotypes.
Results
Generation of an Smst null allele by homologous recombina-
tion. The gene targeting strategy replaced critical Smst
promoter elements and exon 1, which contains the
translational start site for preproSST, with a neo selec-
tion cassette (Figure 1a). One correctly targeted ES cell
clone produced germline-transmitting chimeras that
were the founders for a colony of F2 hybrid mice
(129P2/OlaHsd, C57BL/6J) and, subsequently, N5
incipient congenic C57BL/6J mice. The Smst null allele
was transmitted from mating pairs of Smst+/– mice in a
Mendelian ratio of 1:2:1 for Smst+/+:Smst+/–:Smst–/– geno-
types (Figure 1b). Smst–/– mice of both genetic back-
grounds were healthy and fertile and raised normal lit-
ters. To verify that the gene mutation resulted in the
loss of SST peptides, we analyzed tissue extracts by a
RIA that detects both the 14 and 28 amino acid forms
of SST. SST-like immunoreactivity was reduced by 50%
in stomach and brain from Smst+/– mice and was below
the RIA sensitivity in Smst–/– mice (Figure 1c).
Because SST-containing neurons within the hypo-
thalamus are most directly involved in neuroen-
docrine regulation, we examined this brain area for
evidence of compensatory changes secondary to the
loss of SST. Immunohistochemistry utilizing an SST-
14–directed antiserum revealed a dense plexus of SST
immunoreactive fibers and cell bodies within the
periventricular (PeVN), paraventricular (PVN), arcu-
ate (Arc), and ventromedial (VMH) nuclei of Smst+/+
mice. No specific reaction product was observed in
the hypothalami of Smst–/– mice (Figure 1d), which
appeared structurally normal based on Nissl and
acetylcholinesterase stains (data not shown). A second
antiserum raised against an epitope in the prohor-
mone region of proSST (29) strongly labeled fibers in
the external zone of the median eminence in Smst+/+
but not in Smst–/– mice (Figure 1e). Using a mouse
GHRH antiserum, no apparent differences in either
the number of GHRH-positive neuronal perikarya or
density of fibers in the Arc (Figure 1f) were observed
between Smst+/+ or Smst–/– mice (30).
Effects of sex and genotype on SST and SSTR expression.
Semiquantitative RT-PCR was used to determine
whether SST and SSTR1-5 exhibited baseline sexual
diergism in the mouse as reported previously for SSTR1
and 2 in rat (11), and whether the complete absence of
SST would alter expression of the structurally related
peptide CST or SSTRs in a sex-dependent pattern.
There was a clear sexual diergism in SST gene expres-
sion in wild-type hypothalamus and pituitary gland;
male mice had SST mRNA levels more than twofold
those of female mice in both tissues, and no expression
was detected in the Smst–/– mice (Table 1). In contrast,
CST expression was similar between males and females
in hypothalamus, undetectable in pituitary, and
unchanged in the absence of SST (data not shown).
A complex pattern of altered SSTR expression was
detected in both tissues of Smst–/– mice (Table 1).
SSTR1 expression decreased by more than 50% in the
hypothalamus of both male and female Smst–/– mice
but was unchanged in the pituitaries of these same
mice. In contrast to the absence of sexual diergism in
SSTR1 expression, there was a significant interaction
between sex and genotype on the expression profiles
of SSTR2 and 5. SSTR2 mRNA was increased more
than twofold in the hypothalamus of Smst–/– males
compared with Smst+/+ males but was decreased by
about 70% in the pituitary of both sexes of Smst–/–
mice. SSTR5 mRNA levels increased twofold in the
hypothalamus of both sexes of Smst–/– mice in con-
trast to the twofold increase in pituitary SSTR5
expression that occurred only in Smst–/– males com-
pared with Smst+/+ males. There were no differences
between sexes or genotypes in SSTR3 and 4 mRNA
quantitation (data not shown). An immunocyto-
chemical analysis of SSTR expression showed no qual-
itative differences in receptor localization between
genotypes (Figure 2, a–c). The intensity of immunos-
taining closely paralleled the relative mRNA levels,
indicating that the semiquantitative RT-PCR accu-
rately predicted the changes in SSTR abundance in
the hypothalamus.
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Table 1
Differential expression of SSTR1, 2, and 5, and SST mRNAs in the hypothalamus and pituitary gland of Smst+/+ and Smst–/– mice analyzed by
semiquantitative RT-PCR
Gene Tissue Female Smst+/+ Female Smst–/– Male Smst+/+ Male Smst–/–
SSTR1 Hypothalamus 0.941 ± 0.247 0.437 ± 0.072A 0.992 ± 0.104 0.368 ± 0.040A
Pituitary 0.623 ± 0.143 0.440 ± 0.044 0.518 ± 0.087 0.528 ± 0.017
SSTR2 Hypothalamus 0.326 ± 0.070 0.337 ± 0.048B 0.267 ± 0.009 0.571 ± 0.021A
Pituitary 0.132 ± 0.018 0.040 ± 0.005A 0.170 ± 0.035 0.056 ± 0.019A
SSTR5 Hypothalamus 0.066 ± 0.008 0.134 ± 0.019A 0.054 ± 0.009 0.116 ± 0.011A
Pituitary 0.414 ± 0.023B 0.486 ± 0.013A,B 0.492 ± 0.006 0.906 ± 0.017A
SST Hypothalamus 1.917 ± 0.342B ND 4.710 ± 1.11 ND
Pituitary 0.225 ± 0.012B ND 0.533 ± 0.049 ND
SSTR mRNA was quantified from Southern hybridization signal of RT-PCR products by densitometry using the software Vista Scan (version 2.4; UMAX Tech-
nologies Inc., Fremont, California, USA) and the total intensity (average optical density times area in pixels) was quantified with the Igor Pro analysis software
package (version 3.13; WaveMetrics Inc., Lake Oswego, Oregon, USA). The arbitrary units were corrected for background and expressed as a ratio of β-actin
mRNA in the same sample. Data are expressed as the mean ± SEM of four independent experiments. SSTR, somatostatin receptor; SST, somatostatin; AP <
0.02 versus other genotype in the same sex; BP < 0.02 versus other sex in the same genotype.
Normal growth despite altered GH secretion in SST-deficient
mice. It was apparent from observation of the first litters
of F2 mice that the absence of SST did not result in
either gigantism or a loss of sexual dimorphism in body
size. Growth curves obtained from both F2 (data not
shown) and N5 mice (Figure 3a) confirmed this impres-
sion, although a gradual increase in body weight due to
mild obesity did emerge for male Smst–/– mice after age
18 weeks [repeated measures ANOVA; F(1,14) = 6.1, 
P < 0.05 main effect of genotype; F(10,140) = 3.5, 
P < 0.001 genotype × time interaction]. Smst–/– mice
exhibited the normal sexual dimorphism in body length
that becomes evident during puberty, and there was no
significant increase in body length for either sex of
Smst–/– mice compared with their sibling controls (Fig-
ure 3b). Organ weights of liver and kidney were also nor-
mal in Smst–/– mice (data not shown).
Direct measurement of pulsatile GH in the mouse,
unlike the rat, has been hampered by technical difficul-
ties of chronic blood sampling in unrestrained animals.
In a single reported study, male and female mice showed
equivalent pulse amplitudes, but approximately 1.5-fold
greater pulse frequency in females (35). Therefore to
determine whether SST deficiency was associated with
altered GH secretion, we obtained randomly timed
blood samples by rapid tail bleeds between the hours of
0500 and 2300 from adult male and female mice of
both genotypes over the course of 6 days. A total of 408
plasma samples from 107 mice (26–28 per group) were
assayed for GH (Figure 3c). The box plots demonstrate
that male and female Smst+/+ mice had identical median
GH levels of 3 ng/ml. Furthermore, the overall distri-
bution of values was similar, with the exception that no
female value was greater than 36 ng/ml whereas five of
107 male values ranged from 50 to 122 ng/ml. In
marked contrast, the distribution of GH values was
shifted higher for both male and female Smst–/– mice,
which had medians of 21 and 17 ng/ml, respectively 
(P < 0.0001, Mann-Whitney U test for each paired com-
parison between Smst+/+ and Smst–/– groups). Less than
10% of the random GH values from Smst–/– mice were
below 6 ng/ml compared with 75% for both sexes of
Smst+/+ mice (χ2 = 166.1, P < 0.0001).
Pituitary size was unchanged between the Smst+/+ and
Smst–/– male and female mice. However, pituitary GH
content was reduced by 50% in both sexes of Smst–/– mice
compared with sex-matched controls (F(3,14) = 9.12,
P ≤ 0.01 for each comparison) (Figure 3d), possibly
reflecting an altered balance between GH synthesis and
release. Despite the changes in plasma and pituitary
GH, there was no difference for IGF-1 between Smst+/+
and Smst–/– mice [F(1,21) = 0.25, P = 0.6] (Figure 3e).
To facilitate a comparison between the present data
and that of MacLeod et al. (35), who directly measured
pulsatile GH secretion in cannulated mice at 15-
minute intervals over 8-hour periods, we performed Z
transformations of our GH data sets and the values
from MacLeod’s representative pulsatile GH profiles
(three male and three female outbred CD-1 [ICR] mice;
n = 99 data points for each sex; see original data in ref.
35). The Z transformation approximates a normal dis-
tribution for a data set and then calculates a Z score for
each data point that is equivalent to the number of nor-
malized SDs relative to the group mean. Each of the six
Z-score histograms is skewed to the left (median <
mean) and has a tail extending to the right by as much
as 6 SDs (Figure 4). By visual inspection, the four Z-
score histograms of male and female Smst+/+ mice and
male and female ICR mice are most similar to each
other, whereas the male and female Smst–/– mice appear
to constitute a distinct set because of a greater propor-
tion of 0 < Z < 1. The small percentages of extreme GH
values constituting the positive tails (Z ≥ 1) represent
the peak amplitudes of individual GH pulses in the
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Figure 2
SST receptor expression is altered in the hypothalamus of SST-defi-
cient mice. (a) SSTRs were analyzed by peroxidase immunohisto-
chemistry and the reaction product developed with diaminobenzi-
dine. The hemicoronal hypothalamic sections are at the level of the
median eminence (me). Immunoreactive SSTR1 is expressed in the
arcuate nucleus (Arc), ventromedial nucleus (VMH), and dorsome-
dial nucleus (DMH) of both sexes of Smst+/+ mice and similarly
decreased in both sexes of Smst–/– mice. Bar = 100 µm. (b)
Immunoreactive SSTR2 is expressed in both sexes of Smst+/+ mice and
clearly increased in the Arc, VMH, and DMH of Smst–/– male mice.
(c) Immunoreactive SSTR5 is very sparse in both sexes of Smst+/+ mice
but moderately expressed, particularly in the DMH, of Smst–/– male
mice. III, third ventricle.
MacLeod data sets. Even though the female ICR mice
were directly shown to have a greater GH pulse fre-
quency than male ICR mice (35), resulting in nominal-
ly larger fractions of Z scores ≥ 1 of 14/99 and 9/99,
respectively (Figure 4, lower panels), a χ2 test of this
comparison failed to indicate a significant difference
(Fisher’s Exact P = 0.38) for the group sizes of n = 99.
Hepatic feminization in male SST-deficient mice. To ana-
lyze further the alterations in GH secretory dynamics
of the Smst–/– mice, we took advantage of the firmly
established role of pulsatile GH in regulating sexual
differentiation of the liver (17, 18). Northern blots were
used to quantify mRNA levels of several GH-regulated
genes, and the data were normalized to 18S RNA con-
tent (Figure 5). The male-predominant gene transcripts
for both MUPs group I/II and III exhibited levels that
were approximately fivefold higher in Smst+/+ male
compared with Smst+/+ female mice [F(3,20) = 48.40, P <
0.001]. However, there was a dramatic reduction in
MUPs expression in Smst–/– male mice to levels indis-
tinguishable from females. Identical results were found
in a separate cohort of F2 hybrid mice (data not shown).
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Figure 3
SST-deficient mice retain a normal sexual dimorphism in body size but exhibit altered pituitary GH secretion. (a) Serial body weights of sibling
Smst+/+ and Smst–/– mice (n = 16) generated from N5 B6 congenic Smst+/– parents demonstrate normal growth patterns. The small increase in weight
of male Smst–/– mice after 18 weeks of age is due to increased white adipose tissue without organomegaly (n = 8) (data not shown). (b) Nose-to-
anus body lengths of the mice in a at age 24 weeks are significantly different between sexes but not between genotypes. (c) Box plots of random-
ly obtained serum GH levels from N5 B6 congenic mice of each sex and genotype (n = 97–107) demonstrate significant differences among the
median values of the four groups (P < 0.0001, Kruskal-Wallis test). Individual values in the upper and lower 10% of the population distributions
are plotted as open circles. Data are expressed as nanograms per milliliter in terms of the mouse GH AFP10783B reference preparation. (d) Pitu-
itary GH content at age 20 weeks (n = 4–7) of sibling Smst+/+ and Smst–/– mice generated from F2 hybrid Smst+/– parents is decreased by 50% in both
sexes of Smst–/– mice. (e) Serum IGF-1 levels of the mice in d show no difference between genotypes when the data are collapsed across sex.
Figure 4
Z-score histograms demonstrate similar distributions of GH values
in data sets obtained from randomly timed blood sampling (F+/+,
M+/+, F–/–, and M–/–) or from serial blood sampling in cannulated
mice (F [ICR] and M [ICR]). The GH profiles (n = 97–107 independ-
ent measurements per group) were approximated as standard nor-
mal distributions using a Z-transformation. The top four panels are
the Z scores calculated for the GH data in Figure 3c. The bottom two
panels are the Z scores calculated from the pulsatile GH profiles of
wild-type ICR mice in Figure 1 by MacLeod et al. (35). The Z scores
are grouped into bin sizes equal to 1 SD of the normalized mean for
each group. The bell curve in each panel illustrates the probability of
the standard normal distribution in comparison to the Z scores cal-
culated from the experimental data.
A similar pattern of gene expression across the four
groups was found for albumin, although the increase
in Smst+/+ male compared to Smst+/+ female mice was less
than twofold [F(3,20) = 6.04, P < 0.01]. In contrast, pro-
lactin receptor mRNA levels were more than threefold
higher in Smst+/+ females compared with Smst+/+ males
(P < 0.02, one-tailed t test), consistent with previously
published results in mice for this typical female-pre-
dominant gene (36). The absence of SST resulted in an
increase of prolactin receptor expression in Smst–/– male
compared with Smst+/+ male mice [F(3,20) = 4.91, P <
0.05] but no significant change in Smst–/– female mice.
Finally, we analyzed expression of the female predomi-
nant Cyp450-15α2A4 mRNA in liver (34). Both Smst–/–
male and female mice exhibited a significant increase
in hybridization signal compared with Smst+/+ male
mice [F(3,20) = 6.13, P < 0.05 and < 0.01, respectively].
When all five of the sexually diergic hepatic mRNAs
are considered together, there is a compelling pattern of
feminization in the liver of Smst–/– male mice compared
to wild types, without reciprocal changes in the Smst–/–
female mice. These differences are not due to alterations
in circulating sex steroids in the male mutants because
we found no significant differences between genotypes
for either serum testosterone [Smst+/+ males, 4.6 ± 1.7
ng/ml vs. Smst–/–males, 7.4 ± 2.0 ng/ml; F(1,30)=1.19, 
P = 0.28] or estradiol [Smst+/+ males, 2.0 ± 0.6 pg/ml vs.
Smst–/–males, 9.1 ± 4.5 pg/ml; F(1,30)=2.48, P = 0.13].
SST receptors are also localized on pituitary thy-
rotrophs and SST can inhibit thyroid-stimulating hor-
mone secretion, however serum thyroxine levels did not
differ between sexes or genotypes (Smst+/+ mice, 3.4 ± 0.4
µg/dl vs. Smst–/– mice, 3.7 ± 0.4 µg/dl).
Discussion
SST is synthesized in neural, endocrine and inflammato-
ry cells in the brain and periphery and acts on multiple
targets through a family of five receptors, SSTR1-5, to
produce a broad spectrum of biologic effects (reviewed in
ref. 10). However, many questions still remain concern-
ing the physiological function of SST especially in the
brain. Our present studies were undertaken to create a
mouse model of complete SST deficiency from which we
could infer the functions of the peptide by an analysis of
the phenotype resulting from its absence. A primary aim
was to determine the effects of chronic SST deficiency on
GH secretion and test the hypothesis that male SST-defi-
cient mice would exhibit a more altered phenotype than
females because of the normally greater SST expression
in male hypothalamus. Smst–/– mice were investigated on
both an F2 hybrid and incipient congenic C57BL/6J
genetic background, and equivalent results were obtained
in both strains, indicating that our results are unlikely to
have been biased by selective epistatic interactions of the
Smst gene mutation with other gene alleles from either of
the genetic backgrounds.
The direct measurement of GH pulsatility in mice
represents a formidable challenge and has been report-
ed by only one laboratory (35) to our knowledge. Our
approach to this problem relied on obtaining suffi-
ciently large data sets (n ≅ 100 per group) of randomly
timed plasma GH levels to approximate the true distri-
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Figure 5
GH-dependent hepatic gene expression is
feminized in male SST-deficient mice. The
phosphorimager scans of Northern blots
below the graphs show three representative
samples from each group. Volumetric quan-
titation of each hybridization signal is
expressed as a ratio to the corresponding 18S
RNA signal in arbitrary units (N5 B6 congenic
mice, n = 6). MUPs I, II, and III and albumin
mRNA levels are depressed in male Smst–/–
mice to levels equivalent with all females. In
contrast, levels of the female predominant
transcripts for PrlR and CYP2A4 are signifi-
cantly increased in male Smst–/– mice to levels
equal or greater than female Smst+/+ mice.
Although the cDNA probe used to hybridize
with Cyp450-15α2A4 mRNA also detects a
related, but not sexually diergic, Cyp450-
15α2A5 transcript of identical size (34), the
increased hybridization signal is presumably
due only to a rise in the GH regulated 2A4
transcript. Prolactin receptor, PrlR; Cyp450-
15α2A4/5, CYP2A4.
bution of values that might be obtained by serial meas-
urement of GH from cannulated animals in a formal
pulse-analysis study. The approach was validated by a
comparison of our data from Smst+/+ mice with those of
the representative GH secretory profiles in wild-type
mice published by MacLeod et al. (35) following Z-
transformations to normalize each data set (Figure 4).
It is apparent that the bona fide pulsatile GH data rep-
resented in the bottom two panels have positively
skewed (median < mean), non-Gaussian probability
distributions. The peak values from GH pulses in both
the male and female ICR mice are represented by Z
scores ≥ 1 in the histogram tails. The highly similar dis-
tributions of Z scores between the C57BL/6 Smst+/+ and
MacLeod’s ICR mice suggest that the C57BL/6 Smst+/+
mice secrete GH in a pulsatile rhythm that is similar to
the ICR mice and characterized by large amplitude
pulses and low interpulse nadir levels in both sexes.
In contrast to the Smst+/+ mice, male and female
Smst–/– mice had very few random GH levels < 3 ng/ml
and clearly elevated median GH levels, but the maxi-
mal amplitude of GH was not changed. The Z-score
distributions were similar to the Smst+/+ and wild-type
ICR mice based on positive skew and the presence of
tails ≥ 1, but differed in their larger fraction of scores
between 0 and 1. These data suggest that Smst–/– mice
continue to secrete GH in a pulsatile rhythm, although
SST is apparently required to inhibit GH secretion
between GHRH pulses and thereby maintain low nadir
interpulse GH levels. The decreased pituitary content
of GH is also consistent with increased secretion of
GH into the circulation. However, the Z-transformed
data sets do not have sufficient statistical power to
conclude whether the frequency of GH pulses is
altered in the Smst–/– mice.
Experiments in rats and mice have demonstrated that
there are at least two groups of hepatic genes whose sex-
ually diergic expression is GH dependent, but which dif-
fer in the mechanism of GH regulation. Male-predom-
inant genes, including MUPs and the cytochrome P450
Cyp2d9, are directly activated by pulses of GH secretion
separated by relatively long intervals during which GH
levels are below 1–2 ng/ml (18, 19). This activation of
male-predominant genes is prevented by either the
absence of circulating GH, or conversely, continuous
infusion of GH and subsequent desensitization of the
GH receptor-JAK2/STAT5 signaling complex. Interest-
ingly, even a subtle increase in GH pulse frequency from
six to seven per day, delivered by cannula to hypophy-
sectomized rats, does not support the activation of
male-predominant genes presumably because of the
shortened interpulse interval and suboptimal GH
receptor resensitization (18). In male mice, the inter-
mittent GH pulses also directly repress expression of
female-specific genes including the cytochrome P450
Cyp2a4 by an unknown mechanism (19). Transcrip-
tional regulation of these same genes differs in female
liver in which there is a constitutive activation of female-
specific genes (Cyp2a4) and repression of male-specific
genes (Cyp2d9) that is independent of pituitary GH (37).
An important factor contributing to the female pattern
is normal expression of estrogen receptor-α, presumably
because of its importance in establishing the sexually
dimorphic patterns of GH secretion (34).
Male SST-deficient mice exhibit a striking reduction
in expression of the male-specific genes encoding
MUPs to levels equivalent with normal females. This is
clearly not due to the absence of GH, testosterone, or
thyroxine and, therefore, is strong confirmatory evi-
dence that the normal male pattern of pulsatile GH
secretion is altered in the male Smst–/– mice. The trans-
formation could be due solely to elevated interpulse
levels of GH, consistent with the measured random GH
levels. However, it is also possible that GH pulse fre-
quency is increased according to the model of Tannen-
baum that predicts an intrinsic once-per-hour pul-
satility of GHRH in the absence of a SST-mediated
short-loop feedback inhibition from GH (1). Further
studies using cannulated mice will be necessary to
definitively demonstrate altered GH pulse frequency in
the SST-deficient mice. That IGF-1 levels are not ele-
vated in SST-deficient mice suggests that an increase in
time-integrated GH secretion may be counteracted by
a decrease in GH responsiveness. A loss of the normal
male-like pattern of GH pulsatility is also sufficient to
explain the increased expression of Cyp2a4 and pro-
lactin receptor genes in the male SST-deficient mice
because these gene promoters would no longer be sub-
ject to the transcriptional repression associated with
high-amplitude pulses separated by long interpulse
nadirs. However, the supranormal levels of both Cyp2a4
and prolactin receptor mRNAs in female Smst–/– com-
pared with Smst+/+ mice further suggests the increased
activation of these genes by an unidentified mecha-
nism in addition to derepression.
STAT5b-knockout mice exhibit a similar change in
GH-dependent sexually diergic gene expression com-
pared with the SST-deficient mice, but differ impor-
tantly in their somatic growth (19, 20). Unlike STAT5b
knockouts, both sexes of SST-deficient mice have nor-
mal pubertal growth and retain their sexual dimorphism
in body weight and length. There are several possibilities
to resolve this apparent discrepancy including a reduc-
tion in circulating IGF-1 in the STAT5b-deficient males.
Decreased IGF-1 was also reported in female STAT5b-
deficient mice in one study (19, 20), but normal levels
were demonstrated in an independently generated
strain, possibly because of STAT5b-independent ovari-
an IGF-1 production (19, 20). Both male and female
SST-deficient mice had normal levels of IGF-1, suggest-
ing that the altered secretion of GH that caused femi-
nization of the liver was still sufficient for normal IGF-
1 production in both sexes. Second, we measured a
fraction of the genes known to be regulated by GH in
liver, so it is possible that the change in GH secretion of
SST-deficient mice feminized the expression of fewer
genes than did the absence of STAT5b. Additionally,
there may be other nonhepatic effects of GH important
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for sexual dimorphism in body mass that are sensitive to
the absence of STAT5b but not to changes in GH pul-
satility. Finally, the deletion of STAT5b has polymorphic
effects because it is a component of the signaling com-
plex for several tyrosine kinase receptors (20).
Our results also contrast with the dichotomy between
GH-dependent liver gene expression and somatic growth
reported by Waxman et al. (18) using cannulated rats.
They demonstrated that seven GH pulses per day result-
ed in increased body weight gain over 1 week in both
sexes of hypophysectomized rats that was indistin-
guishable from normal male rats. As noted above, this
GH profile was not recognized by the liver as masculine
because it failed to induce expression of the male-specif-
ic CYP2C11, nor was it recognized as feminine because
it did not stimulate the female predominant steroid 5α-
reductase or suppress the male-specific CYP3A2-depend-
ent testosterone 6β-hydroxylase. Continuous infusion of
GH was required to fully feminize liver gene expression
in male rats, but this latter GH profile resulted in body
weight gain of the males that was reduced to the normal
female level. Therefore, although these data also indicate
disassociations among GH secretory profiles, patterns of
GH-dependent liver gene expression, and somatic
growth, none of the experimentally produced GH pro-
files in hypophysectomized rats preserved a sexually
dimorphic growth response while simultaneously alter-
ing liver gene expression as we observed in the SST-defi-
cient mice. These differences might be attributed to true
species-specific idiosyncrasies between rat and mouse in
their respective GH-hepatic axes or to experimental dif-
ferences including the length of time that body weight
was recorded or the combined actions of pituitary hor-
mones other than GH and their effects on gonadal and
adrenal steroid hormones.
Despite the well-established role of SST as the inhibito-
ry regulator of GH secretion and an important thera-
peutic role of SST-analogues in the treatment of GH-
secreting pituitary tumors, SST-deficient mice up to 2
years of age did not exhibit a clinical syndrome of GH
excess or develop somatotroph hyperplasia or adenoma.
In contrast, overexpression of the stimulatory peptide
GHRH in either mice or humans (38, 39) leads to signif-
icantly increased numbers of pituitary somatotrophs
and a syndrome of gigantism or acromegaly. Taken
together, these findings suggest that SST does not play
a critical physiological role to tonically inhibit soma-
totroph mitogenesis in response to stimulatory growth
factors. This situation is unlike the marked proliferation
of lactotrophs that occurs after genetic disinhibition
from the analogous dopamine and D2 receptor signal-
ing pathway (40, 41). Alternatively, the absence of SST
may be accompanied by a compensatory decrease in the
mitogenic signal from GHRH that was not detected at
the level of immunohistochemical detection of GHRH
neurons in the hypothalamus.
In summary, we have examined the physiological
role of SST in the regulation of GH secretion by a
gene-knockout approach. The absence of SST results
in elevated nadir and median GH levels in both sexes
and a feminized pattern of GH-dependent gene
expression in the liver of male mice. Despite the mag-
nitude of these changes, Smst–/– mice do not exhibit
increased IGF-1 levels or gigantism, and they retain a
normal sexual dimorphism in postnatal somatic
growth. Within the hypothalamus and pituitary, the
loss of SST had pleiotropic effects on the expression of
different SSTR subtypes. Only SSTR2 and SSTR5
exhibited a male-specific increase in mRNA levels in
SST-deficient mice, consistent with a higher function-
al SST tone in the hypothalamus of male compared
with male mice. We conclude that SST is required to
determine the normal secretory profile of GH in both
sexes of mice and specifically to masculinize GH secre-
tion. However, our data indicate that typical mas-
culinized profiles of GH pulsatility and GH-depend-
ent hepatic gene expression are not necessary for the
greater somatic growth characteristics of male com-
pared with female animals after puberty.
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